Astrazeneca (AZN) Net Debt Issuances and Repayments (2009 - 2026)

Astrazeneca (AZN) has reported Net Debt Issuances and Repayments for 16 consecutive years, with $1.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Debt Issuances and Repayments fell 36.3% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $6.9 billion (up 9.67% YoY), while the FY2025 annual figure was $7.8 billion, up 100.13% from the prior year.
• Net Debt Issuances and Repayments came in at $1.6 billion for Q1 2026 at Astrazeneca, up from $896.0 million in the prior quarter.
• The five-year high for Net Debt Issuances and Repayments was $5.0 billion in Q4 2023, with the low at $73.0 million in Q1 2024.
• Average Net Debt Issuances and Repayments over 5 years is $2.0 billion, with a median of $1.7 billion recorded in 2024.
• Across the five-year window, Net Debt Issuances and Repayments tumbled 96.13% in 2024 and soared 3269.86% in 2025, its largest moves.
• Year by year, Net Debt Issuances and Repayments stood at $4.7 billion in 2022, then grew by 5.94% to $5.0 billion in 2023, then tumbled by 65.33% to $1.7 billion in 2024, then plunged by 48.09% to $896.0 million in 2025, then surged by 74.89% to $1.6 billion in 2026.
• According to Business Quant data, Net Debt Issuances and Repayments over the past three periods registered $1.6 billion, $896.0 million, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.